Role of ischemia-modified albumin in estimating the extent and scope of cardiac ischemia in patients with ST elevation myocardial infarction
Jazyk angličtina Země Japonsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- analýza rozptylu MeSH
- balónková koronární angioplastika MeSH
- biologické markery krev MeSH
- časové faktory MeSH
- infarkt myokardu krev diagnóza etiologie patologie terapie MeSH
- ischemická choroba srdeční krev komplikace diagnóza patologie terapie MeSH
- kreatinkinasa, forma MB krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidský sérový albumin MeSH
- lineární modely MeSH
- myokard patologie MeSH
- nekróza MeSH
- prediktivní hodnota testů MeSH
- prognóza MeSH
- senioři MeSH
- sérový albumin MeSH
- stupeň závažnosti nemoci MeSH
- troponin T krev MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- biologické markery MeSH
- ischemia-modified albumin MeSH Prohlížeč
- kreatinkinasa, forma MB MeSH
- lidský sérový albumin MeSH
- sérový albumin MeSH
- troponin T MeSH
Ischemia-modified albumin (IMA) is a laboratory biomarker of cardiac ischemia. Our study aims to determine whether IMA can estimate or represent to any degree the extent of myocardial ischemia. We expect that the higher the marker of cardiac necrosis (maximum value after serial measurements) the greater the preceding cardiac ischemia, indicated by IMA in patients diagnosed with STEMI prior to direct percutaneous coronary intervention (PCI). We studied 216 patients indicated for direct PCI with a diagnosis of ST elevation myocardial infarction. Biochemical analysis of IMA was carried out using the albumin cobalt binding (ACB®) test. We also obtained relevant values for markers of myocardial necrosis (CK, CK-MB, cTnT). In all patients, there was an increased level of IMA prior to the procedure (116 ± 16.9 kU/l); also raised were levels of CK (17.32 μkat/l), CK-MB (4.85 μkat/l) and cTnT (2.97 μg/l) taken as the maximum values obtained after serial measurements at 12, 18, and 24 h after the procedure. We observed that there was no significant association between increase in IMA and cTnT (R2 = 0.0068, p = 0.483). This was also the case for CK-MB (R2 = 0.0011, p = 0.637). IMA does not estimate the extent of ischemia in patients with ST elevation myocardial infarction. However, its absence can be used qualitatively to rule out cardiac ischemia.
Zobrazit více v PubMed
Heart. 2006 Jan;92(1):113-4 PubMed
Clin Chem Lab Med. 2007;45(2):261-2 PubMed
J Am Coll Cardiol. 2007 Jun 19;49(24):2375-6; author reply 2376-7 PubMed
Heart Vessels. 2010 Mar;25(2):87-91 PubMed
Scand J Clin Lab Invest. 2010 Jul;70(4):244-51 PubMed
J Clin Lab Anal. 2010;24(4):273-7 PubMed
Clin Chim Acta. 2009 May;403(1-2):114-20 PubMed
Clin Chim Acta. 2008 Jan;387(1-2):120-7 PubMed
Am J Cardiol. 2003 Aug 1;92(3):322-4 PubMed
Eur Heart J. 2007 Feb;28(3):278-91 PubMed
Clin Chim Acta. 1983 Mar 14;128(2-3):329-35 PubMed
Clin Chim Acta. 2006 May;367(1-2):77-80 PubMed
Clin Chem. 2004 Sep;50(9):1656-60 PubMed
Clin Chem. 2004 Jun;50(6):1063-5 PubMed
Circulation. 1982 Apr;65(4):756-64 PubMed
Clin Chem. 2002 Sep;48(9):1432-6 PubMed
Clin Chem Lab Med. 2004 Apr;42(4):455-61 PubMed
Ann Clin Biochem. 2006 Nov;43(Pt 6):500-2 PubMed
Heart Vessels. 2010 Sep;25(5):374-8 PubMed
Int J Cardiol. 2005 Mar 10;99(1):77-81 PubMed
Am J Cardiol. 2004 Jan 1;93(1):88-90 PubMed
Clin Chem. 2001 Mar;47(3):464-70 PubMed
Heart Vessels. 2008 May;23(3):174-80 PubMed
Clin Chim Acta. 2008 Feb;388(1-2):196-9 PubMed
